VAPAWAY.EU - Research and education on VAP prevention
  • Home
  • Articles
  • GuideLines
  • Links
  • About VAPAWAY
  • Training
  • Contacts

Login








Lost Password?

Register to receive updated data on VAPAWAY initiative

Agenda

 

9 - 12 March 2010

ISICEM International Symposium on Intensive Care and Emergency Medicine - Brussels (Belgium)

ISICEM

 

9 -11 June 2010

EACTA European Association of Cardiothoracic Anaesthesiologists - Edinburgh (UK)

EACTA

 

12-15 June 2010

ESA European Society of Anaesthesiology - Helsinki (Finland)

ESA

 

18-22 September 2010

ERS European Respiratory Society - Barcellona (Spain)

ERS

 

9 -13 October 2010

ESICM European Society of Intensive Care Medicine - Barcellona (Spain)

ESICM

  

 

> International events   

> Local events 

A BAYESIAN DECISION-SUPPORT SYSTEM FOR DIAGNOSING VAP PDF Print E-mail
Wednesday, 16 January 2008
Schurink CA, Visscher S, Lucas PJ, van Leeuwen HJ, Buskens E, Hoff RG, Hoepelman AI, Bonten MJ. University Medical Center Utrecht, Division of Internal Medicine, Geriatrics and Infectious Diseases, Heidelberglaan 100, HP F.02.126, 3584 CX, Utrecht, The Netherlands. Intensive Care Med. 2007 Aug;33(8):1379-86. 


Objective: To determine the diagnostic performance of a Bayesian Decision-Support System (BDSS) for ventilator-associated pneumonia (VAP). DESIGN: A previously developed BDSS, automatically obtaining patient data from patient information systems, provides likelihood predictions of VAP. In a prospectively studied cohort of 872 ICU patients, VAP was diagnosed by two infectious-disease specialists using a decision tree (reference diagnosis). After internal validation daily BDSS predictions were compared with the reference diagnosis. For data analysis two approaches were pursued: using BDSS predictions (a) for all 9422 patient days, and (b) only for the 238 days with presumed respiratory tract infections (RTI) according to the responsible physicians.

Measurements and Results: 157 (66%) of 238 days with presumed RTI fulfilled criteria for VAP. In approach (a), median daily BDSS likelihood predictions for days with and without VAP were 77% [Interquartile range (IQR) = 56-91%] and 14% [IQR 5-42%, p < 0.001, Mann-Whitney U-test (MWU)], respectively. In receiver operating characteristics (ROC) analysis, optimal BDSS cut-off point for VAP was 46%, and with this cut-off point positive predictive value (PPV) and negative predictive value (NPV) were 6.1 and 99.6%, respectively [AUC = 0.857 (95% CI 0.827-0.888)]. In approach (b), optimal cut-off for VAP was 78%, and with this cut-off point PPV and NPV were 86 and 66%, respectively [AUC = 0.846 (95% CI 0.794-0.899)].

Conclusions: As compared with the reference diagnosis, the BDSS had good test characteristics for diagnosing VAP, and might become a useful tool for assisting ICU physicians, both for routinely daily assessment and in patients clinically suspected of having VAP. Empirical validation of its performance is now warranted.
Last Updated ( Thursday, 14 February 2008 )
 
< Prev   Next >
Select and watch
from the following webinars

 


Join us on www.smartonweb.org

Partner

VAPAWAY is proudly supported by Covidien.

http://www.covidien.com